Trump Administration Rejects Expanding Medicare, Medicaid Coverage of Obesity Drugs
The Biden administration had proposed late last year coverage of the popular medicines for obesity.
Fierce Healthcare1h
Medicare Advantage final rule excludes anti-obesity drug coverage under Medicare, Medicaid
The Centers for Medicare and Medicaid Services (CMS) finalized a Medicare Advantage (MA) rule proposed by the Biden ...
RFK Jr. drops plan to have Medicare, Medicaid cover weight loss drugs
More than 7 million people would have gained coverage to the medicine, CMS said when it proposed the rule.
AFN1d
Anti-obesity medications offer an opportunity to cut food waste—and costs
The rise of GLP-1 drugs like Ozempic are changing consumer food waste patterns both at home and in restaurant settings.
Axios on MSN1h
Trump admin won't let Medicare cover anti-obesity drugs
The Trump administration on Friday scrapped a Biden administration proposal to have Medicare cover anti-obesity drugs, ...
Shares of Obesity Drug Makers Lower, Proposal For Medicare Coverage Dropped
Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...
News Medical on MSN5d
Expanding access to anti-obesity medications delivers 13% return on investment for society
A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...
Medicare and Medicaid will not cover weight loss drugs, Trump administration decides
The Trump administration has decided against implementing a proposal for Medicare and Medicaid to cover weight loss drugs, the Centers for Medicare and Medicaid Services said in a filing published ...
BenefitsPRO7h
Supporting employees on weight loss medications: A new era of workplace health
Whether or not you choose to cover weight loss drugs, offering holistic support can make a meaningful difference in employee ...
Lohud.com, Westchester County on MSN1dOpinion
New York needs equity for obesity treatment. That starts with Medicaid coverage | Opinion
New York’s reputation as a trailblazer for health equity is in danger. We must ensure equity in obesity treatment.
Managed Healthcare Executive3d
Prime Therapeutics Finds No Medical Cost Offsets for GLP-1 Obesity Drugs | AMCP Annual 2025
A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...
Op-Ed: Now is the time for members of Congress to support efforts that combat obesity
As the old saying goes, “an ounce of prevention is worth a pound of cure,” and in my decades of experience in healthcare that ...